Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Decreased expression of stomatin predicts poor prognosis in HER2-positive breast cancer ; volume:16 ; number:1 ; day:30 ; month:8 ; year:2016 ; pages:1-8 ; date:12.2016
BMC cancer ; 16, Heft 1 (30.8.2016), 1-8, 12.2016
- Creator
-
Chen, Chin-Yau
- Contributor
-
Yang, Chih-Yung
Chen, Yen-Chung
Shih, Chia-Wen
Lo, Su-Shun
Lin, Chi-Hung
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2681-7
- URN
-
urn:nbn:de:1111-201609281176
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:03 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chen, Chin-Yau
- Yang, Chih-Yung
- Chen, Yen-Chung
- Shih, Chia-Wen
- Lo, Su-Shun
- Lin, Chi-Hung
- SpringerLink (Online service)
Other Objects (12)
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
High score of LDH plus dNLR predicts poor survival in patients with HER2-positive advanced breast cancer treated with trastuzumab emtansine
A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
Nanotechnology approaches to addressing HER2-positive breast cancer
How We Treat HER2-Positive Metastatic Breast Cancer
Progress and challenges in HER2-positive gastroesophageal adenocarcinoma